Traws Pharma Faces Delisting Concerns
Ticker: TRAW · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00, $1 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Traws Pharma might be getting delisted, check exchange status.
AI Summary
Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on September 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a potential transfer of listing, with the earliest event reported on September 24, 2024.
Why It Matters
This filing signals potential issues with Traws Pharma's compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to severe stock price declines and reduced liquidity.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- September 24, 2024 (date) — Earliest event reported
- September 27, 2024 (date) — Filing date
FAQ
What specific listing rule or standard has Traws Pharma, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Traws Pharma, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the significance of the 'Transfer of Listing' mentioned in the filing?
The mention of 'Transfer of Listing' suggests that the company may be moving its stock from one exchange to another, possibly due to the delisting concerns or as a strategic move.
When was the earliest event reported that led to this 8-K filing?
The earliest event reported in this filing occurred on September 24, 2024.
What was Traws Pharma, Inc. previously known as?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
What is the primary business of Traws Pharma, Inc. according to the filing?
According to the filing, Traws Pharma, Inc. is in the business of Pharmaceutical Preparations, with a Standard Industrial Classification code of 2834.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-09-27 17:10:55
Key Financial Figures
- $1.00 — a minimum closing bid price of at least $1.00 per share. Under Nasdaq Listing Rule 5
- $1 m — id price is currently trading above the $1 minimum bid price, there can be no assura
Filing Documents
- tm2425081d1_8k.htm (8-K) — 26KB
- 0001104659-24-103773.txt ( ) — 194KB
- tmb-20240924.xsd (EX-101.SCH) — 3KB
- tmb-20240924_lab.xml (EX-101.LAB) — 33KB
- tmb-20240924_pre.xml (EX-101.PRE) — 22KB
- tm2425081d1_8k_htm.xml (XML) — 4KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 25, 2023, Traws Pharma, Inc. (the "Company") received a letter from The Nasdaq Capital Market ("Nasdaq") indicating that the Company has failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires that companies listed on Nasdaq maintain a minimum closing bid price of at least $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180 calendar day grace period, or until March 25, 2024, to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the Company's common stock has a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the 180 calendar day grace period. The Company did not regain compliance with the minimum bid price requirement by March 25, 2024. On March 27, 2024, the Company received a letter from Nasdaq granting the Company a second 180 calendar day period to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A), or until September 23, 2024. Their determination to grant the second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement, and its notification to Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. On September 24, 2024, the Company received a letter from the Nasdaq Staff (the "Staff") stating that the Company had not been able to regain compliance with the minimum bid price requirement, and that the Staff had determined to seek to delist the Company's securities from Nasdaq unless the Company requests a hearing before the Nasdaq Hear